再発または難治性多発性骨髄腫の参加者を対象に、タルケタマブとダラツムマブの併用、またはダラツムマブとポマリドマイドの併用と、ダラツムマブとポマリドマイドおよびデキサメタゾンの併用を比較する研究 (MonumenTAL-3)
タルケタマブとダラツムマブ (SC) およびポマリドマイド (Tal-DP) の組み合わせ、またはタルケタマブ (SC) とダラツムマブ SC (Tal-D) の組み合わせと、ダラツムマブ SC、ポマリドマイドおよびデキサメタゾン (DPd) の組み合わせを比較する第 3 相ランダム化試験-少なくとも1つの以前の治療ラインを受けた再発または難治性の多発性骨髄腫
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
アクセスの拡大
連絡先と場所
研究場所
-
-
Arizona
-
Tucson、Arizona、アメリカ、85719
- The University of Arizona Cancer Center
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72205
- University of Arkansas for Medical Sciences
-
-
Connecticut
-
Norwalk、Connecticut、アメリカ、06850
- Norwalk Hospital-oncology
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20007
- MedStar Georgetown University Hospital
-
Washington D.C.、District of Columbia、アメリカ、20037
- George Washington University
-
-
Florida
-
Hollywood、Florida、アメリカ、33021
- Memorial Healthcare System
-
Miami、Florida、アメリカ、33136
- University of Miami Health System
-
-
Illinois
-
Chicago、Illinois、アメリカ、60612
- University Of Illinois
-
-
Kansas
-
Westwood、Kansas、アメリカ、66205
- University of Kansas
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70112
- Tulane University Hospital & Clinics
-
New Orleans、Louisiana、アメリカ、70121-2429
- Ochsner Health System
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21205
- Johns Hopkins University
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02118
- Boston University Medical Center
-
Boston、Massachusetts、アメリカ、02114
- Massachusetts General
-
Worcester、Massachusetts、アメリカ、01655
- University of Massachusetts Medical School
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109
- University of Michigan Health System
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- University Of Minnesota
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216
- University of Mississippi Medical Center
-
-
Missouri
-
St Louis、Missouri、アメリカ、63110-1032
- Washington University School Of Medicine
-
-
New Jersey
-
New Brunswick、New Jersey、アメリカ、08901
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York、New York、アメリカ、10016
- NYU Langone Health
-
Syracuse、New York、アメリカ、13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- University of North Carolina
-
Charlotte、North Carolina、アメリカ、28204
- Levine Cancer Institute, Carolinas HealthCare System
-
Charlotte、North Carolina、アメリカ、28204
- Novant Health 1
-
Winston-Salem、North Carolina、アメリカ、27157
- Wake Forest Baptist Medical Center
-
Winston-Salem、North Carolina、アメリカ、27103
- Novant Health
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- University Hospitals Cleveland Medical Center
-
Columbus、Ohio、アメリカ、43214
- OhioHealth
-
Columbus、Ohio、アメリカ、43210
- The Ohio State University Wexner Medical Center - James Cancer Hospital
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19107-4215
- Thomas Jefferson University
-
-
South Carolina
-
Charleston、South Carolina、アメリカ、29425-8900
- Medical University of South Carolina
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38120
- Baptist Cancer Center
-
-
Texas
-
Houston、Texas、アメリカ、77030
- MD Anderson Cancer Center
-
Houston、Texas、アメリカ、77030
- Houston Methodist Hospital
-
Lubbock、Texas、アメリカ、79410
- Joe Arrington Cancer Research Treatment Center
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- Huntsman Cancer Institute
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22903
- University of Virginia
-
Richmond、Virginia、アメリカ、23298
- Virginia Commonwealth University - Massey Cancer Center
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- Fred Hutchinson Cancer Research Center
-
-
-
-
-
Blackpool、イギリス、FY3 8NR
- Blackpool Victoria Hospital
-
Dundee、イギリス、DD1 9SY
- Ninewells Hospital & Medical School
-
London、イギリス、W12 0HS
- Hammersmith Hospital
-
Newcastle upon Tyne、イギリス、NE7 7DN
- Newcastle Freeman Hospital
-
Nottingham、イギリス、NG5 1PB
- Nottingham City Hospital
-
Plymouth、イギリス、PL6 8DH
- University Hospitals Plymouth NHS Trust
-
Sutton、イギリス、SM2 5PT
- Royal Marsden Hospital
-
Wolverhampton、イギリス、WV10 0QP
- New Cross Hospital
-
-
-
-
-
Afula、イスラエル、1834111
- Ha'Emek Medical Center
-
Be’er Ya‘aqov、イスラエル、70300
- Shamir Medical Center Assaf Harofeh
-
Hadera、イスラエル、3810101
- Hillel Yaffe Medical Center
-
Haifa、イスラエル、31096
- Rambam Medical Center
-
Haifa、イスラエル、31048
- Bnai Zion Medical Center
-
Haifa、イスラエル、34362
- Carmel Medical Center
-
Jerusalem、イスラエル、9103102
- Shaare Zedek Medical Center
-
Nahariya、イスラエル、22100
- Galilee Medical Center
-
Petah Tikva、イスラエル、49100
- Beilinson medical center
-
Ramat Gan、イスラエル、52621
- Sheba Medical Center
-
Safed、イスラエル、13100
- Ziv Medical Center
-
Tel Aviv、イスラエル、6423906
- Sourasky (Ichilov) Medical Center
-
-
-
-
-
Ancona、イタリア、60126
- A.O. Universitaria Ospedali Riuniti di Ancona
-
Bari、イタリア、70124
- Policlinico di Bari
-
Bologna、イタリア、40138
- Azienda Ospedaliera Policlinico S. Orsola-Malpighi
-
Brescia、イタリア、25123
- Azienda Ospedaliera Spedali Civili di Brescia
-
Catania、イタリア、95123
- PO G.Rodolico, AOU Policlinico-Vittorio Emanuele Catania
-
Milan、イタリア、20162
- ASST Grande Ospedale Metropolitano Niguarda
-
Milan、イタリア、20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Padova、イタリア、35128
- Azienda Ospedaliera Universitaria di Padova
-
Palermo、イタリア、90146
- Ospedale Villa Sofia-Cervello
-
Pavia、イタリア、27100
- Fondazione IRCCS Policlinico San Matteo
-
Reggio Emilia、イタリア、42123
- Arcispedale Santa Maria Nuova - IRCCS
-
Roma、イタリア、00193
- Presidio Ospedaliero Santo Spirito in Sassia
-
San Giovanni Rotondo、イタリア、71013
- IRCCS Ospedale Casa Sollievo della Sofferenza
-
Torino、イタリア、10126
- A.O.U. Città della Salute e della Scienza
-
-
-
-
-
Dordrecht、オランダ、3318 AT
- Albert Schweitzer ziekenhuis-lokatie Dordwijk
-
Eindhoven、オランダ、5631 BM
- Maxima Medisch Centrum
-
Rotterdam、オランダ、3015
- Erasmus MC
-
-
-
-
-
Athens Attica、ギリシャ、115 28
- Alexandra General Hospital of Athens
-
Thessaloniki、ギリシャ、546 39
- Anticancer Hospital of Thessaloniki Theageneio
-
Thessalonikis、ギリシャ、570 10
- G Papanikolaou Hospital of Thessaloniki
-
-
-
-
-
Badalona、スペイン、08916
- Hosp. Univ. Germans Trias I Pujol
-
Barcelona、スペイン、08041
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona、スペイン、08036
- Hosp Clinic de Barcelona
-
Barcelona、スペイン、08035
- Hosp Univ Vall D Hebron
-
El Palmar、スペイン、30120
- Hosp. Univ. Virgen de La Arrixaca
-
Jerez de la Frontera、スペイン、11407
- Hosp. de Jerez de La Frontera
-
León、スペイン、24071
- Hosp. de Leon
-
Madrid、スペイン、28041
- Hosp. Univ. 12 de Octubre
-
Madrid、スペイン、28034
- Hosp. Univ. Ramon Y Cajal
-
Madrid、スペイン、28006
- Hosp. Univ. de La Princesa
-
Madrid、スペイン、28050
- Hosp Univ Hm Sanchinarro
-
Málaga、スペイン、29010
- Hosp Virgen de La Victoria
-
Pamplona、スペイン、31008
- Clinica Univ. de Navarra
-
Salamanca、スペイン、37007
- Hosp Clinico Univ de Salamanca
-
San Cristóbal de La Laguna、スペイン、38320
- Hosp. Univ. de Canarias
-
Valencia、スペイン、46017
- Hosp. Univ. Dr. Peset
-
-
-
-
-
Brno、チェコ、625 00
- Fakultni nemocnice Brno
-
Hradec Králové、チェコ、500 05
- Fakultni nemocnice Hradec Kralove
-
Olomouc、チェコ、779 00
- Fakultni nemocnice Olomouc
-
Ostrava - Poruba、チェコ、708 52
- Fakultni Nemocnice Ostrava
-
Prague、チェコ、100 34
- Fakultni nemocnice Kralovske Vinohrady
-
Prague、チェコ、128 08
- Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie
-
-
-
-
-
Ankara、トルコ(Türkiye)、06680
- Liv Hospital Ankara
-
Ankara、トルコ(Türkiye)、06200
- Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Hematology Unit
-
Ankara、トルコ(Türkiye)、06590
- Ankara University Medical Faculty
-
Antalya、トルコ(Türkiye)、07100
- Antalya Egitim ve Arastirma Hastanesi
-
Istanbul、トルコ(Türkiye)、34093
- Istanbul University Istanbul Medical Faculty
-
Istanbul、トルコ(Türkiye)、34214
- Medipol Mega University Hospital
-
Istanbul、トルコ(Türkiye)、34153
- Cerrahpasa Tip Fakultesi Prof. Dr. Murat Dilmener Hastanesi
-
Izmir、トルコ(Türkiye)、35330
- Dokuz Eylul University Medical Faculty
-
Samsun、トルコ(Türkiye)、55139
- Ondokuz Mayis University
-
-
-
-
-
Berlin、ドイツ、12203
- Charite Campus Benjamin Franklin
-
Cologne、ドイツ、50937
- Universitaetsklinikum Koeln
-
Hamburg、ドイツ、22763
- Asklepios Klinik Altona
-
Heidelberg、ドイツ、69120
- Universitaetsklinikum Heidelberg
-
Leipzig、ドイツ、04103
- Universitaetsklinikum Leipzig
-
Mainz、ドイツ、55131
- Universitätsmedizin der Johannes Gutenberg Universität
-
Würzburg、ドイツ、97080
- Universitaetsklinikum Wuerzburg
-
-
-
-
-
Créteil、フランス、94010
- APHP - Hopital Henri Mondor
-
Dijon、フランス、21000
- CHU Dijon
-
Lyon、フランス、69008
- Centre Leon Berard
-
Montpellier、フランス、34295
- CHU de Montpellier - Hopital Saint-Eloi
-
Nantes、フランス、44093
- CHU de Nantes hotel Dieu
-
Nice、フランス、06202
- CHU HOPITAL DE L'ARCHET - Hematology
-
Paris、フランス、75571
- CHU Hopital Saint Antoine
-
Pessac、フランス、33604
- CHRU - Hôpital du Haut Lévêque - Centre François Magendie
-
Toulouse、フランス、31059
- Institut Universitaire du cancer de Toulouse-Oncopole
-
-
-
-
-
Barretos、ブラジル、14784 400
- Fundacao Pio XII
-
Belo Horizonte、ブラジル、30150-221
- Santa Casa de Misericordia de Belo Horizonte
-
Brasília、ブラジル、70390-140
- IDOR - Regional Brasilia
-
Caxias do Sul、ブラジル、95070 560
- Fundacao Universidade de Caxias do Sul
-
Curitiba、ブラジル、81520-060
- Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
-
Florianópolis、ブラジル、88020 210
- Grupo ELORA Centro de Pesquisa e Ensino em Saude de Santa Catarina
-
Natal、ブラジル、59062-000
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre、ブラジル、90050-170
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Ribeirão Preto、ブラジル、14051140
- Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto
-
Rio de Janeiro、ブラジル、22775 001
- Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
-
Salvador、ブラジル、41253-190
- IDOR - Regional Bahia
-
São Paulo、ブラジル、01321-001
- Real e Benemerita Associacao Portuguesa de Beneficencia
-
São Paulo、ブラジル、01308 901
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes
-
São Paulo、ブラジル、01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo、ブラジル、01323-000
- Hospital Paulistano
-
São Paulo、ブラジル、04537 081
- Clinica Medica Sao Germano LTDA
-
São Paulo、ブラジル、01401 002
- IDOR - Regional Sao Paulo
-
-
-
-
-
Brussels、ベルギー、1090
- UZ Brussel
-
Edegem、ベルギー、2650
- UZA
-
Hasselt、ベルギー、3500
- Virga Jessa Ziekenhuis
-
Liège、ベルギー、4000
- CHC MontLegia
-
Ottignies、ベルギー、1340
- Clinique Saint Pierre
-
Yvoir、ベルギー、5530
- UCL Mont Godinne
-
-
-
-
-
Brzozów、ポーランド、36-200
- Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
-
Gdansk、ポーランド、80 214
- Uniwersyteckie Centrum Kliniczne
-
Katowice、ポーランド、40 519
- Pratia Onkologia Katowice
-
Kielce、ポーランド、25 734
- Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
-
Krakow、ポーランド、30 688
- Szpital Uniwersytecki w Krakowie
-
Lublin、ポーランド、20090
- Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli
-
Olsztyn、ポーランド、10-228
- Szpital Kliniczny MSWiA z Warminsko Mazurskim Centrum Onkologii w Olsztynie Oddzial Hematologii
-
Szczecin、ポーランド、71-252
- Uniwersytecki Szpital Kliniczny Nr 1 PUM im prof Tadeusza Sokolowskiego w Szczecinie
-
Torun、ポーランド、87 100
- Wojewodzki Szpital Zespolony im L Rydygiera w Toruniu
-
Warsaw、ポーランド、02-781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Wroclaw、ポーランド、50 367
- Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
-
-
-
-
-
Beijing、中国、100034
- Peking University First Hospital
-
Beijing、中国、100006
- Peking Union Medical College Hospital
-
Changchun、中国、130021
- The First Hospital of Jilin University
-
Changsha、中国、410000
- The second Xiangya Hospital of Central South University
-
Chaoyang District、中国、100020
- Beijing Chaoyang Hospital
-
Chengdu、中国、610072
- Sichuan Academy of Medical Science Sichuan Provincial Peoples Hospital
-
Fuzhou、中国、350001
- Fujian Medical University Union Hospital
-
Guangzhou、中国、510080
- Guangdong Provincial People's Hospital
-
Guangzhou、中国、510710
- Sun Yat Sen University Cancer Center
-
Hangzhou、中国、310003
- The First Affiliated Hospital Zhejiang University College of Medicine
-
Nanjing、中国、210008
- Nanjing Drum Tower Hospital
-
Shanghai、中国、200065
- Tongji Hospital of Tongji University
-
Shanghai、中国、200434
- Shanghai Fourth People s Hospital
-
Shenzhen、中国、518036
- Peking University Shenzhen Hospital
-
Suzhou、中国、215006
- First Affiliated Hospital SooChow University
-
Tianjin、中国、300320
- Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science
-
Tianjin、中国、300060
- Tianjin cancer hospital
-
Wuhan、中国、430030
- Tongji Hospital, Tongji Medical College of HUST
-
Zhengzhou、中国、450008
- Henan Cancer Hospital
-
-
-
-
-
Kaohsiung City、台湾、83301
- Kaohsiung Chang Gung Memorial Hospital
-
Kaohsiung City、台湾、80756
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Taichung、台湾、40447
- China Medical University Hospital
-
Tainan、台湾、704
- National Cheng Kung University Hospital
-
Taipei、台湾、10048
- National Taiwan University Hospital
-
-
-
-
-
Bunkyō City、日本、113 8519
- Institute of Science Tokyo Hospital
-
Chiba、日本、260-8717
- Chiba Cancer Center
-
Fukuoka、日本、814-0180
- Fukuoka University Hospital
-
Gifu、日本、503-8502
- Ogaki Municipal Hospital
-
Gunma、日本、371-0034
- Gunma University Hospital
-
Hirakata、日本、573 1191
- Kansai Medical University Hospital
-
Hyōgo、日本、670-8540
- Japanese Red Cross Society Himeji Hospital
-
Kamakura-shi、日本、247-8533
- Shonan Kamakura General Hospital
-
Kashiwa、日本、277 8577
- National Cancer Center Hospital East
-
Koshigaya、日本、343-8555
- Dokkyo Medical University Saitama Medical Center
-
Kumamoto、日本、860-8556
- Kumamoto University Hospital
-
Kyoto、日本、603-8151
- Kyoto Kuramaguchi Medical Center
-
Matsumoto、日本、399-8701
- National Hospital Organization Matsumoto Medical Center
-
Niigata、日本、951-8566
- Niigata Cancer Center Hospital
-
Nishinomiya Shi、日本、663 8501
- Hyogo Medical University Hospital
-
Sapporo、日本、060-8648
- Hokkaido University Hospital
-
Sendai、日本、980 8574
- Tohoku University Hospital
-
Shiwa-gun、日本、028-3695
- Iwate Medical University Hospital
-
Suita、日本、565 0871
- The University of Osaka Hospital
-
Tokyo、日本、135 8550
- The Cancer Institute Hospital of JFCR
-
Ōtake、日本、739-0696
- National Hospital Organization Hiroshima-Nishi Medical Center
-
-
-
-
-
Busan、韓国、602 812
- Dong-A University Hospital
-
Gyeonggi-do、韓国、10408
- National Cancer Center
-
Incheon、韓国、21565
- Gachon University Gil Medical Center
-
Jeollanam-do、韓国、58128
- Chonnam National University Hwasun Hospital
-
Jeonju、韓国、54907
- Jeonbuk National University Hospital
-
Seoul、韓国、03080
- Seoul National University Hospital
-
Seoul、韓国、05505
- Asan Medical Center
-
Seoul、韓国、03722
- Severance Hospital Yonsei University Health System
-
Seoul、韓国、06351
- Samsung Medical Center
-
Seoul、韓国、06591
- The Catholic University of Korea Seoul St Marys Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Documented multiple myeloma as defined: a) Multiple myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria and b) Measurable disease at screening as defined by any of the following: i) Serum M-protein level greater than or equal to (>=) 0.5 grams per deciliter (g/dL) (central laboratory); ii) Urine M-protein level >= 200 milligram (mg) per 24 hours (central laboratory); iii) Light chain multiple myeloma without measurable M-protein in the serum or the urine: serum immunoglobulin free light chain >= 10 milligram per deciliter (mg/dL) (central laboratory), and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Relapsed or refractory disease as defined by: i) Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease by IMWG criteria greater than (>) 60 days after cessation of treatment; ii) Refractory disease is defined as less than (<) 25 percent (%) reduction in monoclonal paraprotein (M-protein) or confirmed progressive disease by IMWG criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
- Received at least 1 prior line of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide. Participants who have received only 1 prior line of antimyeloma therapy must be considered lenalidomide-refractory (that is, have demonstrated progressive disease by IMWG criteria on or within 60 days of completion of lenalidomide-containing regimen). Participants who have received >=2 prior lines of antimyeloma therapy must be considered lenalidomide exposed
- Documented evidence of progressive disease based on investigator's determination of response by the IMWG criteria on or after their last regimen
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 at screening and immediately prior to the start of administration of study treatment
Exclusion Criteria:
- Contraindications or life-threatening allergies, hypersensitivity, or intolerance to study drug excipients
- Disease is considered refractory to an anti-cluster of differentiation 38 (CD38) monoclonal antibody as defined per IMWG consensus guidelines (progression during treatment or within 60 days of completing therapy with an anti-CD38 monoclonal antibody)
- Received prior pomalidomide therapy
- A maximum cumulative dose of corticosteroids to >=140 milligrams (mg) of prednisone or equivalent within 14-day period before the first dose of study drug
- Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required
- Plasma cell leukemia (per IMWG criteria) at the time of screening, Waldenström's macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS syndrome), or primary amyloid light chain amyloidosis
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm A: Talquetamab Subcutaneous (SC) in Combination With Daratumumab SC and Pomalidomide (Tal-DP)
Participants will receive talquetamab and daratumumab as SC injections; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Upon sponsor notification, participants will enter the Long-Term Extension (LTE) Phase or Drug Access Long-term Extension (DA-LTE) Phase and will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent or any other criteria specified is fulfilled. |
Talquetamab will be administered subcutaneously.
他の名前:
Pomalidomide will be administered orally. Dexamethasone will be administered orally or intravenously. Daratumumab will be administered subcutaneously. |
|
実験的:Arm B: Daratumumab in Combination With Pomalidomide and Dexamethasone (DPd)
Participants will receive daratumumab as SC injection; pomalidomide will be self-administered as a single dose orally; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Upon sponsor notification, participants will enter the Long-Term Extension (LTE) Phase or Drug-access Long-term Extension (DA-LTE) Phase and will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent or any other criteria specified is fulfilled. |
Pomalidomide will be administered orally. Dexamethasone will be administered orally or intravenously. Daratumumab will be administered subcutaneously. |
|
実験的:Arm C: Talquetamab SC in Combination With Daratumumab SC (Tal-D)
Participants will receive talquetamab and daratumumab as SC injection; dexamethasone may be given orally or intravenously as a pretreatment medication and study drug. Upon sponsor notification, participants will enter the Long-Term Extension (LTE) Phase or Drug-access Long-term Extension (DA-LTE) Phase and will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent or any other criteria specified is fulfilled. |
Talquetamab will be administered subcutaneously.
他の名前:
Dexamethasone will be administered orally or intravenously. Daratumumab will be administered subcutaneously. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS)
時間枠:Up to 6 years 6 months
|
PFS is defined as time from the date of randomization to the first documentation of disease progression, or death due to any cause, whichever is reported first. |
Up to 6 years 6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Response (Partial Response [PR] or Better)
時間枠:Up to 6 years 6 months
|
Overall response (PR or better) is defined as percentage of participants who have a PR or better per International Myeloma Working Group (IMWG) criteria. |
Up to 6 years 6 months
|
|
Very Good Partial Response (VGPR) or Better Rate
時間枠:Up to 6 years 6 months
|
VGPR or better rate is defined as the percentage of participants who achieve a VGPR or better according to IMWG response criteria. |
Up to 6 years 6 months
|
|
Complete Response (CR) or Better Rate
時間枠:Up to 6 years 6 months
|
CR or better rate is defined as the percentage of participants who achieve CR or better according to IMWG response criteria. |
Up to 6 years 6 months
|
|
Overall Minimal Residual Disease (MRD) Negative CR
時間枠:Up to 6 years 6 months
|
MRD-negative CR is defined as proportion of participants with CR or stringent CR who achieve MRD negativity at a threshold of 10^-5 at any timepoint after the first dose of study drug and before disease progression or start of subsequent antimyeloma therapy. |
Up to 6 years 6 months
|
|
Overall Survival (OS)
時間枠:Up to 6 years 6 months
|
OS is defined as the time from the date of randomization to the date of the participant's death. |
Up to 6 years 6 months
|
|
Progression-free Survival on Next-line Therapy (PFS2)
時間枠:Up to 6 years 6 months
|
PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first. |
Up to 6 years 6 months
|
|
Time to Next Therapy (TTNT)
時間枠:Up to 6 years 6 months
|
TTNT is defined as the time from randomization to the start of subsequent antimyeloma treatment. |
Up to 6 years 6 months
|
|
Number of Participants with Adverse Events (AEs)
時間枠:Up to 6 years 6 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 6 years 6 months
|
|
Number of Participants with AEs by Severity
時間枠:Up to 6 years 6 months
|
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). |
Up to 6 years 6 months
|
|
Serum Concentrations of Talquetamab
時間枠:Up to 6 years 6 months
|
Serum concentrations of talquetamab will be reported. |
Up to 6 years 6 months
|
|
Serum Concentrations of Daratumumab
時間枠:Up to 6 years 6 months
|
Serum concentrations of daratumumab will be reported. |
Up to 6 years 6 months
|
|
Number of Participants with Presence of Anti-Drug Antibodies (ADAs) to Talquetamab
時間枠:Up to 6 years 6 months
|
Number of participants with presence ADAs to talquetamab will be reported. |
Up to 6 years 6 months
|
|
Number of Participants With Presence of Anti-Drug Antibodies (ADAs) to Daratumumab
時間枠:Up to 6 years 6 months
|
Number of participants with presence of ADAs to daratumumab will be reported. |
Up to 6 years 6 months
|
|
Time to Worsening in Symptoms, Functioning, and Overall Health-Related Quality of Life (HRQoL) as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q)
時間枠:Up to 6 years 6 months
|
The MySIm-Q is a disease-specific PRO assessment complementary to the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 item (EORTC-QLQ-C30). |
Up to 6 years 6 months
|
|
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by PROMIS Short Form Version 2.0 -Physical Functioning 8c
時間枠:Up to 6 years 6 months
|
The Patient-reported Outcomes Measurement Information System (PROMIS) Short Form Version 2.0 -Physical Function 8c is an 8-item fixed--length short form derived from the PROMIS Physical Function item bank. |
Up to 6 years 6 months
|
|
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30
時間枠:Up to 6 years 6 months
|
Time to worsening in symptoms, functioning, and HRQoL as assessed by EORTC-QLQ-C30 will be reported. |
Up to 6 years 6 months
|
|
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by PRO-CTCAE
時間枠:Up to 6 years 6 months
|
The National Cancer Institute's (NCI) PRO-CTCAE is an item library of common AEs experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. |
Up to 6 years 6 months
|
|
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
時間枠:Up to 6 years 6 months
|
The EQ-5D-5L is a generic measure of health status. For purposes of this study, the EQ-5D-5L will be used to generate utility scores for use in cost-effectiveness analyses. |
Up to 6 years 6 months
|
|
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by Patient Global Impression - Severity (PGI-S)
時間枠:Up to 6 years 6 months
|
The PGI-S will be used as an anchor, external criterion, to determine meaningful change in scores for the MySIm-Q and PROMIS SF PF 8c in this population. |
Up to 6 years 6 months
|
|
Change From Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q)
時間枠:Baseline up to 6 years 6 months
|
The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. |
Baseline up to 6 years 6 months
|
|
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by PROMIS Short Form Version 2.0 -Physical Functioning 8c
時間枠:Baseline up to 6 years 6 months
|
The Patient-reported Outcomes Measurement Information System (PROMIS) Short Form Version 2.0 -Physical Function 8c is an 8-item fixed-length short form derived from the PROMIS Physical Function item bank. |
Baseline up to 6 years 6 months
|
|
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30
時間枠:Baseline up to 6 years 6 months
|
Change from baseline in symptoms, functioning, and HRQoL as assessed by EORTC-QLQ-C30 will be reported. |
Baseline up to 6 years 6 months
|
|
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by PRO-CTCAE
時間枠:Baseline up to 6 years 6 months
|
The National Cancer Institute's (NCI) PRO-CTCAE is an item library of common AEs experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. |
Baseline up to 6 years 6 months
|
|
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L)
時間枠:Baseline up to 6 years 6 months
|
The EQ-5D-5L is a generic measure of health status. For purposes of this study, the EQ-5D-5L will be used to generate utility scores for use in cost-effectiveness analyses. |
Baseline up to 6 years 6 months
|
|
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by Patient Global Impression - Severity (PGI-S)
時間枠:Baseline up to 6 years 6 months
|
The PGI-S will be used as an anchor, external criterion, to determine meaningful change in scores for the MySIm-Q and PROMIS SF PF 8c in this population. |
Baseline up to 6 years 6 months
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CR109082
- 2021-000202-22 (EudraCT番号)
- 64407564MMY3002 (その他の識別子:Janssen Research & Development, LLC)
- 2023-503467-41-00 (レジストリ識別子:EUCT number)
- 2023 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。